CNS Pharmaceuticals (NASDAQ:CNSP) Issues Quarterly Earnings Results

CNS Pharmaceuticals (NASDAQ:CNSP – Get Free Report) posted its quarterly earnings results on Monday. The company reported ($0.24) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.27) by $0.03, FiscalAI reports.

CNS Pharmaceuticals Stock Performance

NASDAQ:CNSP opened at $2.99 on Monday. The firm has a market cap of $4.37 million, a PE ratio of -0.13 and a beta of 3.21. CNS Pharmaceuticals has a fifty-two week low of $1.90 and a fifty-two week high of $10.54. The business has a 50 day moving average price of $4.96 and a 200-day moving average price of $4.47.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of CNS Pharmaceuticals in a report on Thursday, October 15th. One investment analyst has rated the stock with a Sell rating. According to data from MarketBeat, the stock has a consensus rating of “Sell”.

Read Our Latest Research Report on CNS Pharmaceuticals

CNS Pharmaceuticals Company Profile

(Get Free Report)

CNS Pharmaceuticals is a biopharmaceutical company focused on developing treatments for cancers of the brain and central nervous system. Its research has centered on investigational therapies intended to address the challenges of treating tumors that affect these areas. The company’s lead candidate has been berubicin, an experimental anthracycline designed to cross the blood-brain barrier. CNS Pharmaceuticals has evaluated berubicin for glioblastoma, an aggressive form of brain cancer. The drug remains investigational and is not an approved treatment.

Featured Stories

Earnings History for CNS Pharmaceuticals (NASDAQ:CNSP)

Receive News & Ratings for CNS Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CNS Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.